Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that a patent application.
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that a patent application.
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, announces that, pursuant to the redemption, sale and conversion of convertible unsecured loan
H.C. Wainwright Investment Conference
2020 has not exactly been a great year for IPOs. The pandemic has meant two things.
So Tirupati is slightly unusual because they’ve launched a first of its kind IPO offer for retail investors via PrimaryBid, providing retail with the same investment opportunity and terms as
The Coronavirus pandemic has had a massive impact on the UK economy. A contraction of more than 20 per cent in the three months to June, means that we are
Pires Investments plc (AIM: PIRI), the investment company focused on next generation technology, is pleased to announce its unaudited interim results for the six-month period ended 30 April 2020.
As Highly As Their Investments?
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases.
I’ve written about Hemogenyx before, especially into the run up to and during the Great Covid-19 stocks rally of 2020.
While the Pilbara in Western Australia is more commonly known for its iron ore mining, in recent years it has been gold discoveries making the headlines.